K T Park

4PUBLICATIONS
2CO-AUTHORS
Biologically active moleculesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Dec 31, 2021
Treatment-refractory ulcerative colitis responsive to indigo naturalis.

Julie P Saiki, Johan Ol Andreasson, Kevin V Grimes

|Jun 08, 2018
Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.

K T Park, L Sceats, M Dehghan

|Mar 13, 2018
Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis.

Blaise Hamel, May Wu, Elizabeth O Hamel

|Nov 23, 2017
Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

H Yu, D MacIsaac, J J Wong

Pageof 1

Frequent Collaborators

1 joint publications

Julie P Saiki

1 joint publications

Lyn R Frumkin